The Liquid Biopsy: ctDNA, Circulating Tumour Cells and Bloodborne Biomarkers
Thursday 8th March 2018
Royal Society of Medicine, 1 Wimpole Street, London, W1G 0LZ
More about this event
The CM-Path biomarker workshop series aims at discussing the current and future challenges of innovative biomarker developments, and agreeing on the barriers for delivery of clinical diagnostics assays. The second workshop is organized by the CM-Path Discovery Workstream for the following objectives:
- Circulating tumour cell and ctDNA – where are we now?
- Recent advances in technology – where are we going?
- Applications in research and clinical trials
- Benefits and barriers to widespread adoption in clinical practice
The Consensus Statement was written in collaboration with:
The Cancer Research UK Precision Medicine team is pioneering a number of collaborative initiatives which aim to tailor treatment and care to individual patients based on the molecular specific make-up of their disease cancer.
The PHG Foundation, part of the University of Cambridge, is a non-profit think tank focused on how emerging health technologies can provide more effective, personalised healthcare for patients and citizens.
The Consensus Statement has been endorsed by:
Genomics England is a company owned by the Department of Health and Social Care, and was set up to deliver the 100,000 Genomes Project. The aim is to create a new genomic medicine service for the NHS – transforming the way people are cared for. Patients may be offered a diagnosis where there wasn’t one before. In time, there is the potential of new and more effective treatments.